Abstract: Objective: To explore the expression and clinical significance of hsa-miR-9 in colon carcinoma. Methods:Tissue samples were collected from 62cases of colon carcinoma from June 2007to December 2009, with paracancerous tissues as the normal controls. Hybridization in situ and real-time quantitative polymerase chain reaction were used to detect the hsa-miR- 9 expression in those specimens. The relationship between hsa-miR- 9 expression and the clinicopathologic parameters was determined. Results: Hy-bridization in situ showed that the positive expression rate of the hsa-miR- 9 was 88.71% in colon carcinoma and17.74% in the paracan-cerous tissues; the difference was statistically significant (P < 0.01). The real-time quantitative PCR showed that the expression of hsa-miR- 9 was (3.77± 0.42) times higher in colon carcinoma than in normal tissue; the differences were statistically significant ( P < 0.01). This indicates that the upregulation of hsa-miR- 9 expression is associated with advanced clinical stages. It was 4.23± 0.18and 2.24± 0.31times higher than paracancerous tissues, respectively, for stage III/IV and stage I/II colon carcinoma; the difference was sta -tistically significant in different groups ( P < 0.05). The expression of hsa-miR-9 was 3.12times higher with lymph node metastasis than without lymph node metastasis in colon carcinoma; the difference was statistically significant ( P < 0.01). The expression of hsa-miR- 9 was not associated with degree of differentiation; the difference was not statistically significant ( P > 0.05). Conclusion: Hsa-miR- 9 is related to the occurrence and metastasis of colon carcinoma, and it could be a predictive biomarker in the treatment and prognosis of colon carcinoma.